> Astellas' Dificlir, Sanofi's ($SNY) Lemtrada and Lundbeck's Selincro are a few of the contenders up for the 2014 Innovative Drug Award. Report
> IMS Health has announced it intends to acquire certain Cegedim information solutions and Customer Relationship Management businesses for €385 million ($520 million) in cash. Release
> Forest Laboratories' ($FRX) Viibryd performed significantly better than a placebo for treating generalized anxiety disorder, three late-stage studies show. Report
> Alexion ($AXLN) and Cincinnati Children's Hospital Medical Center have announced the establishment of a collaboration and fund for the advancement of research in rare disease. Release
> A University of Tokyo investigation panel found 'serious faults' in a Novartis ($NVS) significant input of company employees in the trial's planning stages. More
And Finally... Eli Lilly's ($LLY) new online board game, "Destination Discovery," helps users experience the challenges of "bringing a new medicine from molecule to medicine cabinet." More